Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA examines cause of valsartan impurity

Executive Summary

The US Food and Drug Administration (FDA) says a “major operation” is underway to investigate and address the “troubling finding” of a toxic impurity in some generic versions of valsartan that could cause cancer, leading the agency to also test all drugs in valsartan’s therapeutic class for traces of the toxic material.

You may also be interested in...



Drug Safety Announcement Blitz Highlights Gottlieb's PR Savvy As Shutdown Drags On

Release of several different safety announcements showcases US FDA Commissioner Gottlieb's efforts to quell potential public concerns with an active communication strategy. 

First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve

Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.

Estonian Biobank’s Personalized Medicine Project To Unlock New Insights For Drug R&D

A new center for personalized medicine in Estonia will see PacBio’s long-read whole genome sequencing technology used to unlock new information about how genetics impact patients’ drug responses, experts from the project tell the Pink Sheet.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB001157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel